Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-928-5300
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees18
Next Earnings Date11/14/2019 (Estimated)
OptionableNot Optionable
Chiasma (NASDAQ:CHMA) Frequently Asked Questions
What is Chiasma's stock symbol?
Chiasma trades on the NASDAQ under the ticker symbol "CHMA."
How were Chiasma's earnings last quarter?
Chiasma Inc (NASDAQ:CHMA) posted its earnings results on Thursday, August, 8th. The biotechnology company reported ($0.25) EPS for the quarter, beating the Zacks' consensus estimate of ($0.29) by $0.04. View Chiasma's Earnings History.
When is Chiasma's next earnings date?
What price target have analysts set for CHMA?
5 analysts have issued 1 year target prices for Chiasma's stock. Their predictions range from $11.00 to $18.00. On average, they anticipate Chiasma's share price to reach $14.00 in the next year. This suggests a possible upside of 175.0% from the stock's current price. View Analyst Price Targets for Chiasma.
What is the consensus analysts' recommendation for Chiasma?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chiasma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chiasma.
Has Chiasma been receiving favorable news coverage?
Media coverage about CHMA stock has been trending negative this week, according to InfoTrie Sentiment. The research group rates the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Chiasma earned a news sentiment score of -2.0 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Chiasma.
Are investors shorting Chiasma?
Chiasma saw a increase in short interest in September. As of September 30th, there was short interest totalling 2,210,000 shares, an increase of 53.5% from the August 30th total of 1,440,000 shares. Based on an average trading volume of 799,800 shares, the days-to-cover ratio is currently 2.8 days. Approximately 7.4% of the shares of the stock are sold short. View Chiasma's Current Options Chain.
Who are some of Chiasma's key competitors?
Some companies that are related to Chiasma include Eagle Pharmaceuticals (EGRX), Dova Pharmaceuticals (DOVA), G1 Therapeutics (GTHX), CannTrust (CNTTF), Cara Therapeutics (CARA), Principia Biopharma (PRNB), Omeros (OMER), Axsome Therapeutics (AXSM), Vanda Pharmaceuticals (VNDA), Rhythm Pharmaceuticals (RYTM), Organogenesis (ORGO), Stoke Therapeutics (STOK), Wave Life Sciences (WVE), Kura Oncology (KURA) and Emisphere Technologies (EMIS).
What other stocks do shareholders of Chiasma own?
Who are Chiasma's key executives?
Chiasma's management team includes the folowing people:
- Mr. Mark J. Fitzpatrick, Pres, CEO, Sec. & Director (Age 56)
- Mr. Drew Enamait, VP of Fin. & Admin. and Principal Accounting Officer (Age 45)
- Dr. William H. Ludlam, Sr. VP of Clinical Devel. & Medical Affairs (Age 54)
- Dr. Gary Patou, Head of Clinical (Age 60)
When did Chiasma IPO?
(CHMA) raised $76 million in an IPO on Thursday, July 16th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. Barclays and Cowen and Company acted as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.
Who are Chiasma's major shareholders?
Chiasma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Meeder Asset Management Inc. (0.03%). Company insiders that own Chiasma stock include Mark J Fitzpatrick, Roni Mamluk, Scott Minick and William Ludlam. View Institutional Ownership Trends for Chiasma.
Which institutional investors are buying Chiasma stock?
CHMA stock was bought by a variety of institutional investors in the last quarter, including Meeder Asset Management Inc.. Company insiders that have bought Chiasma stock in the last two years include Mark J Fitzpatrick, Scott Minick and William Ludlam. View Insider Buying and Selling for Chiasma.
How do I buy shares of Chiasma?
Shares of CHMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Chiasma's stock price today?
One share of CHMA stock can currently be purchased for approximately $5.09.
How big of a company is Chiasma?
Chiasma has a market capitalization of $213.55 million. The biotechnology company earns $-31,260,000.00 in net income (profit) each year or ($1.28) on an earnings per share basis. Chiasma employs 18 workers across the globe.View Additional Information About Chiasma.
What is Chiasma's official website?
How can I contact Chiasma?
Chiasma's mailing address is 460 Totten Pond Road Suite 530, Waltham MA, 02451. The biotechnology company can be reached via phone at 617-928-5300 or via email at [email protected]
MarketBeat Community Rating for Chiasma (NASDAQ CHMA)
MarketBeat's community ratings are surveys of what our community members think about Chiasma and other stocks. Vote "Outperform" if you believe CHMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CHMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
